News

January 3, 2018

Aivita Launches Phase 2 Trial of Dendritic Cell Immunotherapy for Ovarian Cancer

News

Aivita Biomedical has initiated a Phase 2 trial of a new kind of dendritic cell immunotherapy for certain types of ovarian cancer. The therapy uses a patient’s own dendritic cells, ... Read more

December 22, 2017December 22, 2017

Phase 1 Study Showing COTI-2 Safe in Potentially Treating Advanced Ovarian and Other Cancers

News

Initial data from an early clinical trial in patients with advanced ovarian and other cancers found a potential oral therapy, COTI-2, to be safe at varying doses, supporting a more advanced ... Read more

December 20, 2017

Tesaro’s Zejula for Recurrent Ovarian Cancer Now Available in Germany

News

Zejula (niraparib), an oral therapy for patients with recurrent ovarian cancer, is now available in Germany, according to Tesaro, the biopharma that developed the therapy. “The introductions of Zejula in Germany and ... Read more

December 18, 2017December 18, 2017

Masitinib Counteracts Resistance to Ovarian Cancer Therapy in Cell Cultures

News

Researchers discovered how AB Science’s therapy masitinib — a veterinary medicine sold as Kinavet in the U.S. — acts to re-sensitize drug-resistant tumor cells to the anti-cancer treatment Gemzar (gemcitabine). ... Read more

December 15, 2017

Mouse Study Reveals Potential Combination Therapy for Ovarian Cancer

News

Researchers at the Johns Hopkins Kimmel Cancer Center have discovered a combination therapy that may hold promise in halting ovarian cancer progression. The combination of epigenetic therapy and immunotherapy reduced ... Read more

December 13, 2017

First Recurrent Ovarian Cancer Patient Dosed with FATE-NK100 in APOLLO Trial

News

The first ovarian cancer patient in the APOLLO Phase 1 clinical trial has been dosed with FATE-NK100, Fate Therapeutics‘ investigational NK (natural killer) cell therapy. The Phase 1 trial (NCT03213964), which ... Read more

December 11, 2017

Higher Levels of Tumor T-cells Predict Better Survival Rates in Certain Ovarian Cancer Patients, Study Finds

News

The levels of certain white blood cells in tumors correlate with longer overall survival in patients with some types of epithelial ovarian cancer, regardless of first-line chemotherapy or the extent ... Read more

December 8, 2017

FDA Grants Rubraca Speedy Review for Use as Ovarian Cancer Maintenance Treatment

News

The U.S. Food and Drug Administration (FDA) has granted Priority Review Status to Clovis Oncology’s application to expand its approval for Rubraca (rucaparib) to include recurrent ovarian cancer maintenance treatment. A decision ... Read more

December 6, 2017

Cytori Ready to Seek EU Approval of ATI-0918 as Bioequivalent to Caelyx for Ovarian Cancer

News

Cytori Therapeutics reports that their compound ATI-0918 is equivalent to Janssen’s Caelyx (doxorubicin) — a previously approved liposomal formulation of doxorubicin hydrochloride for the treatment of ovarian cancer. The data stems ... Read more

December 4, 2017December 4, 2017

Long Non-coding RNAs Found Linked to Ovarian Cancer Metastasis, Study Shows

News

Researchers have found a set of long non-coding RNAs (lncRNAs) – RNA molecules with no protein-coding capacity – that participate in the metastatic process of ovarian cancer cells. Inhibiting one ... Read more